Scientech Research LLC’s Intellia Therapeutics NTLA Stock Holding History

Scientech Research LLC’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Buy	72,533 +56,268	+346%	+$788K	0.99%	35
2026 Q1	$209K	Sell	16,265 -2,301	-12%	-$29.3K	0.17%	232
2025 Q4	$167K	Sell	18,566 -9,521	-34%	-$131K	0.11%	365
2025 Q3	$485K	Buy	+28,087	New	+$346K	0.17%	260
2024 Q4	–	Sell	-39,262	Closed	-$807K	–	770
2024 Q3	$807K	Sell	39,262 -7,839	-17%	-$181K	0.16%	255
2024 Q2	$1.05M	Buy	47,101 +26,884	+133%	+$640K	0.22%	170
2024 Q1	$556K	Buy	20,217 +9,776	+94%	+$272K	0.29%	118
2023 Q4	$318K	Buy	+10,441	New	+$300K	0.32%	109

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Scientech Research LLC's NTLA Position: Q2 2026 in Review

Scientech Research LLC increased its Intellia Therapeutics (NTLA) stake by 346% in Q2 2026, buying an estimated $788K and bringing the position to 72,533 shares worth $1.23M. The position accounts for 0.99% of the portfolio, ranked #35.

Scientech Research LLC first reported a position in NTLA in Q4 2023 and has held it in 8 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Scientech Research LLC held 72,533 shares of Intellia Therapeutics worth $1.23M as of Q2 2026.
Scientech Research LLC bought 56,268 Intellia Therapeutics shares in Q2 2026, an estimated $788K.
Intellia Therapeutics made up 0.99% of Scientech Research LLC's portfolio in Q2 2026, its #35 holding.
Scientech Research LLC first reported a position in Intellia Therapeutics in Q4 2023 and has held it in 8 quarters since.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.